SHARE

AstraZeneca signs $4.7bn obesity drugs partnership with China’s CSPC

The pharmaceutical group has secured exclusive global rights outside China to CSPC’s weight-loss injections, strengthening its obesity pipeline. The agreement includes $1.2bn upfront and milestones, alongside plans to invest $15bn in China by 2030.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.